Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX:V BTI) announces that subject to regulatory approval it will grant additional options in the amount of 50,000 to Brisco Capital Partners Corp. and 50,000 to Graeme Dick pursuant to their IR Consulting Agreement as amended as well as 50,000 to Hamza Thindal Capital Corporation pursuant to their Marketing Consulting Communications Agreement as amended. The options are exercisable for two years at $1.23 per share and each grant is subject to vesting over 12 months as follows: 12,500 three months after date of grant and 12,500 each three months thereafter.
biOasis Technologies Inc. is a biopharmaceutical company engaged in the development and commercialization of products for the diagnosis and treatment of neurological diseases and disorders.
Forward Looking Statements
“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”
On Behalf of the Board of Directors
Robin Hutchison Chairman & CEO